<DOC>
	<DOCNO>NCT02658916</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability multiple intravenous ( IV ) infusion BMS-986168 patient Progressive Supranuclear Palsy ( PSP ) . The study also assess pharmacodynamic ( PD ) effect BMS-986168 cerebrospinal fluid ( CSF ) extracellular tau ( eTau ) , pharmacokinetics ( PK ) , immunogenicity BMS-986168 patient Progressive Supranuclear Palsy .</brief_summary>
	<brief_title>Extension Study BMS-986168 Patients With Progressive Supranuclear Palsy Who Participated CN002003</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<criteria>1 . Completed treatment Study CN002003 . 2 . A diagnosis probable possible PSP consistent Study CN002003 criteria new medical information diagnosis since enrollment Study CN002003 might confer doubt PSP diagnosis . 3 . Able tolerate Magnetic Resonance Imaging ( MRI ) . 4 . Able perform protocolspecified assessment comply study visit schedule . 5 . Have reliable caregiver accompany patient study visit . Caregiver must able read , understand , speak local language fluently ensure comprehension inform consent informantbased assessment patient . Caregiver must also frequent contact patient ( least 3 hour per week one time different time ) willing monitor patient 's health concomitant medication throughout study . 6 . Patient must reside outside skilled nursing facility dementia care facility time enrollment 7 . Women childbearing potential ( WOCBP ) sexually active fertile men partner WOCBP must use highly effective birth control . 1 . Presence unstable , clinically significant medical condition PSP include , limited : hematological , endocrine , cardiovascular , renal , hepatic , gastrointestinal , immunological , psychological neurological disease malignancy . 2 . Contraindication undergo lumbar puncture ( LP ) . 3 . Recent drug alcohol abuse define Diagnostic Statistical Manual Mental Disorders ( 4th Edition ) . 4 . Treatment investigational drug ( include placebo ) BMS986168 placebo give Study CN002003 device within 90 day prior enrollment 5 . Any vaccination within 30 day prior study drug administration . 6 . Contraindication MRI examination reason 7 . Any sound medical , psychiatric , and/or social reason determine investigator 8 . Known history human immunodeficiency virus . 9 . Evidence organ dysfunction significant deterioration prior value CN002003 beyond consistent target population would place patient increase risk risk early study discontinuation . 10 . Inability venipunctured and/or tolerate venous access . 11 . History allergy , hypersensitivity , serious adverse reaction monoclonal antibody relate compound allergy component study drug</criteria>
	<gender>All</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>86 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>